Agile Therapeutics, Inc. provided revenue guidance for the First quarter 2023. For the period, the Company expects net revenue is expected to be in the range of $3.8 to $4.0 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3749 USD | 0.00% | -0.74% | -80.77% |
05-15 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $5.7M | MT |
03-28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
1st Jan change | Capi. | |
---|---|---|
-80.77% | 2.57M | |
+12.24% | 116B | |
+12.44% | 106B | |
-8.87% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.52% | 16.33B | |
+6.15% | 14.14B | |
+29.21% | 12.02B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Provides Revenue Guidance for the First Quarter 2023